Traitement en cours

Veuillez attendre...

Paramétrages

Paramétrages

Aller à Demande

1. WO1990005445 - OLIGONUCLEOTIDES NON CODANTS DU PROTO-ONCOGENE C-MYB ET LEURS EMPLOIS

Note: Texte fondé sur des processus automatiques de reconnaissance optique de caractères. Seule la version PDF a une valeur juridique

[ EN ]

CLAIMS

1. A pharmaceutical composition comprising a pharmaceutical carrier and an oligonucleotide which has a nucleotide sequence complementary to at least a portion of the mRNA transcript of the human c-myb gene, said oligonucleotide being hybridizable to said mRNA transcript.
2. A composition according to claim 1 wherein the oligonucleotide comprises an at least a 15-mer oligodeoxynucleotide.
3. A composition according to claim 2 wherein the oligodeoxynucleotide has a deoxynucleotide sequence complementary to a portion of the c-myb mRNA transcript including the translation initiation codon of said transcript.
4. A composition according to claim 2 wherein the oligodeoxynucleotide has a deoxynucleotide sequence complementary to a portion of the c-myb mRNA transcript beginning with the codon immediately downstream from the translation initiation codon of said transcript.
5. A composition according to claim 2 wherein the oligodeoxynucleotide has a deoxynucleotide sequence complementary to a portion of the c-myb mRNA transcript which includes at least a portion of the 5 ' -untranslated region of said transcript.
6. A composition according to claim 2 wherein the oligodeoxynucleotide comprises from a 15-mer to a 21-mer.

7. A composition according to claim 4 wherein the oligodeoxynucleotide is selected from the group of oligodeoxynucleotide consisting of:
5 ' -GCT GTG CCG GGG TCT TCG GGC-3 ' ,
5 ' -CT GTG CCG GGG TCT TCG GGC-3 * ,
5 ' -T GTG CCG GGG TCT TCG GGC-3 ' ,
5 ' -GTG CCG GGG TCT TCG GGC-3 ' , 5 ' -TG CCG GGG TCT TCG GGC-3 ' ,
5 ' -G CCG GGG TCT TCG GGC-3 ' and
5 ' -CCG GGG TCT TCG GGC-3 ' .
8. A composition according to claim 7 wherein the oligodeoxynucleotide comprises 5' -GTG CCG GGG TCT TCG GGC-3 ' .
9. A composition according to claim 5 wherein the oligodeoxynucleotide is selected from the group of oligodeoxynucleotides consisting of:
5 ' -CCG GGG TCT TCG GGC CAT GGG-3 ' ,
5 ' -CG GGG TCT TCG GGG CAT GGG-3 ' ,
5 ' -G GGG TCT TCG GGC CAT GGG-3 ' ,
5 ' -GGG TCT TCG GGC CAT GGG-3 ' ,
5 » -GG TCT TCG GGC CAT GGG-3 ' ,
5 ' -G TCT TCG GGC CAT GGG-3 ' and
5 ' -TCT TCG GGC CAT GGG-3 ' .
10. A composition according to claim 9 wherein the oligodeoxynucleotide comprises 5' -GGG TCT TCG GGC CAT GGG-3 ' .
11. An oligonucleotide which has a nucleotide sequence complementary to at least a portion of the mRNA transcript of the human c-myb gene, said oligonucleotide being hybridizable to said mRNA transcript.
12. An oligonucleotide according to claim 11 which comprises at least a 15-mer oligodeoxynucleotide.
13. An oligodeoxynucleotide according to claim 12 which has a deoxynucleotide sequence complementary to a portion of the c-myb mRNA transcript including the translation initiation codon of said transcript.
14. An oligodeoxynucleotide according to claim 12 which has a deoxynucleotide sequence complementary to a portion of the c-myb mRNA transcript beginning with the codon immediately downstream from the translation initiation codon of said transcript.

15. An oligodeoxynucleotide according to claim 12 which has a deoxynucleotide sequence complementary to a portion of the c-myb mRNA transcript which includes at least a portion of the 5 ' -untranslated region of said transcript.
16. An oligodeoxynucleotide according to claim 12 which comprises from a 15-mer to a 21-mer.
17. An oligodeoxynucleotide according to claim 14 selected from the group consisting of:
5 ' -GCT GTG CCG GGG TCT TCG GGC-3 ' ,
5 ' -CT GTG CCG GGG TCT TCG GGC-3 ' ,
5 ' -T GTG CCG GGG TCT TCG GGC-3 ' ,
5 ' -GTG CCG GGG TCT TCG GGC-3 ' ,
5 ' -TG CCG GGG TCT TCG GGC-3 ' ,
5 ' -G CCG GGG TCT TCG GGC-3 ' and
5 ' -CCG GGG TCT TCG GGC-3 ' .
18. An oligodeoxynucleotide according to claim 17 wherein the oligodeoxynucleotide comprises 5 ' -GTG CCG GGG TCT TCG GGC-3 ' .
19. An oligodeoxynucleotide according to claim 15 selected from the group consisting of:
5 ' -CCG GGG TCT TCG GGC CAT GGG-3 ' ,
5 ' -CG GGG TCT TCG GGG CAT GGG-3 ' ,
5 ' -G GGG TCT TCG GGC CAT GGG-3 ' ,
5 ' -GGG TCT TCG GGC CAT GGG-3 ' ,
5 ' -GG TCT TCG GGC CAT GGG-3 ' ,
5'-G TCT TCG GGC CAT GGG-31 and
5 * -TCT TCG GGC CAT GGG-3 ' .
20. An oligodeoxynucleotide according to claim 19 wherein the oligodeoxynucleotide comprises 5' -GGG TCT TCG GGC CAT GGG-3 ' .
21. A method for treating hematologic neoplasms in vivo or ex vivo comprising administering to an individual or cells harvested from such individual an effective amount of an oligonucleotide which has a nucleotide sequence complementary to at least " a portion of the mRNA transcript of the human c-myb gene, said oligonucleotide being hybridizable to said mRNA transcript.
22. The method according to claim 21 wherein the oligonucleotide is an at least 15-mer oligodeoxynucleotide.
23. A method according to claim 22 wherein the oligodeoxynucleotide has a deoxynucleotide sequence complementary to a portion of the c-myb mRNA transcript including the translation initiation codon of said transcript.
24. A method according to claim 22 wherein the oligodeoxynucleotide has a deoxynucleotide sequence complementary to a portion of the c-myb mRNA transcript beginning with the codon immediately downstream from the translation initiation codon of said transcript.
25. A method according to claim 22 wherein the oligodeoxynucleotide has a deoxynucleotide sequence complementary to a portion of the c-myb mRNA transcript which includes at least a portion of the 5 '-untranslated region of said transcript.
26. A method according to claim 22 wherein the oligodeoxynucleotide comprises from a 15-mer to a 21-mer.

27. A method according to claim 24 wherein the oligodeoxynucleotide is selected from the group consisting of:
5' -GCT GTG CCG GGG TCT TCG GGC-3
5'-CT GTG CCG GGG TCT TCG GGC-3
5'-T GTG CCG GGG TCT TCG GGC-3
5' -GTG CCG GGG TCT TCG GGC-3
5'-TG CCG GGG TCT TCG GGC-3
5 ' -G CCG GGG TCT TCG GGC-3 ' and
5 '-CCG GGG TCT TCG GGC-3

28. A method according to claim 27 wherein the oligodeoxynucleotide comprises 5' -GTG CCG GGG TCT TCG GGC-3 ' .
29. A method according to claim 25 wherein the oligodeoxynucleotide is selected from the group of oligodeoxynucleotides consisting of:
5« -CCG GGG TCT TCG GGC CAT GGG-3 ' ,
5 ' -CG GGG TCT TCG GGG CAT GGG-3 ' ,
5 ' -G GGG TCT TCG GGC CAT GGG-3 ' ,
5' -GGG TCT TCG GGC CAT GGG-3 ' ,
5 l-GG TCT TCG GGC CAT GGG-3 ' ,
5 « -G TCT TCG GGC CAT GGG-3 ' and
5 ' -TCT TCG GGC CAT GGG-3 ' .
30. A method according to claim 29 wherein the oligodeoxynucleotide comprises 5' -GGG TCT TCG GGC CAT GGG-3 ' .
31. A method according to any of claims 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 comprising treating aspirated bone marrow cells.
32. A method for inducing immunosuppression comprising administering to an individual an effective amount of an oligonucleotide which has a nucleotide sequence complementary to at least a portion of the mRNA transcript of the human c-myb gene, said oligonucleotide being hybridizable to said mRNA transcript.
33. A method according to qlaim 32 wherein the oligonucleotide is an at least 15-mer oligodeoxynucleotide.
34. A method according to claim 33 wherein the oligodeoxynucleotide has a deoxynucleotide sequence complementary to a portion of the c-myb mRNA transcript including the translation initiation codon of said transcript.
35. A method according to claim 33 wherein the oligodeoxynucleotide has a deoxynucleotide sequence complementary to a portion of the c-myb mRNA transcript beginning with the codon immediately downstream from the translation initiation codon of said transcript.
36. A method according to claim 33 wherein the oligodeoxynucleotide has a deoxynucleotide sequence complementary to a portion of the c-myb mRNA transcript which includes at least a portion of the 5 ' -untranslated region of said transcript.
37. A method according to claim 33 wherein the oligodeoxynucleotide comprises from a 15-mer to a 21-mer.

38. A method according to claim 35 wherein the oligodeoxynucleotide is selected from the group consisting of:
5 '-GCT GTG CCG GGG TCT TCG GGC-3
5'-CT GTG CCG GGG TCT TCG GGC-3
5'-T GTG CCG GGG TCT TCG GGC-3
5' -GTG CCG GGG TCT TCG GGC-3
5'-TG CCG GGG TCT TCG GGC-3
5 ' -G CCG GGG TCT TCG GGC-3 • and
5' -CCG GGG TCT TCG GGC-3
39. A method according to claim 38 wherein the oligodeoxynucleotide comprises 5 ' -GTG CCG GGG TCT TCG GGC-3 ' .